|
β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→3)- [β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→6)]- β- D- Man- (1→4)- β- D- GlcpNAc- (1→4)- [α- L- Fucp- (1→6)]- β- D- GlcpNAc |
|
CHEBI:70967 |
|
beta- D- Galp- (1- >4)- beta- D- GlcpNAc- (1- >2)- alpha- D- Manp- (1- >3)- [beta- D- Galp- (1- >4)- beta- D- GlcpNAc- (1- >2)- alpha- D- Manp- (1- >6)]- beta- D- Man- (1- >4)- beta- D- GlcpNAc- (1- >4)- [alpha- L- Fucp- (1- >6)]- beta- D- GlcpNAc |
|
A branched amino decasaccharide consisting of a hexasaccharide chain of β-D-galactose, N-acetyl-β-D-glucosamine, α-D-mannose, β-D-mannose, and two N-acetyl-β-D-glucosamine residues linked sequentially (1→4), (1→2), (1→3), (1→4) and (1→4), to the β-D-mannose residue of which is (1→6)-linked a β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosaminyl-(1→3)-α-D-mannosyl trisaccharide branch and to the reducing end N-acetyl-β-D-glucosamine residue of which is (1→6)-linked an α-L-fucose residue. When it is the N-glycan content of the tumour necrosis factor (TNF) alpha blocker adalimumab, the two terminal galactose residues may be either absent or alternatively the linkage to the GlcNAc residues may be (1→3), while the fucose residue may be absent. |
|
 
This entity has been manually annotated by the ChEBI Team.
|
|
ZINC000096086436 |
|
Molfile
XML
SDF
|
|
|
|
InChI=1S/C68H114N4O50/c1- 15- 33(84) 43(94) 48(99) 63(106- 15) 104- 14- 28- 55(39(90) 29(59(103) 107- 28) 69- 16(2) 80) 116- 60- 30(70- 17(3) 81) 40(91) 54(26(12- 79) 112- 60) 119- 66- 51(102) 56(120- 68- 58(47(98) 37(88) 23(9- 76) 111- 68) 122- 62- 32(72- 19(5) 83) 42(93) 53(25(11- 78) 114- 62) 118- 65- 50(101) 45(96) 35(86) 21(7- 74) 109- 65) 38(89) 27(115- 66) 13- 105- 67- 57(46(97) 36(87) 22(8- 75) 110- 67) 121- 61- 31(71- 18(4) 82) 41(92) 52(24(10- 77) 113- 61) 117- 64- 49(100) 44(95) 34(85) 20(6- 73) 108- 64/h15,20- 68,73- 79,84- 103H,6- 14H2,1- 5H3,(H,69,80) (H,70,81) (H,71,82) (H,72,83) /t15- ,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34- ,35- ,36+,37+,38+,39+,40+,41+,42+,43+,44- ,45- ,46- ,47- ,48- ,49+,50+,51- ,52+,53+,54+,55+,56- ,57- ,58- ,59+,60- ,61- ,62- ,63+,64- ,65- ,66- ,67- ,68+/m0/s1 |
WWOGFSBVRNWZBV-KVMLNOKXSA-N |
C[C@@H] 1O[C@@H] (OC[C@H] 2O[C@@H] (O) [C@H] (NC(C) =O) [C@@H] (O) [C@@H] 2O[C@@H] 2O[C@H] (CO) [C@@H] (O[C@@H] 3O[C@H] (CO[C@H] 4O[C@H] (CO) [C@@H] (O) [C@H] (O) [C@@H] 4O[C@@H] 4O[C@H] (CO) [C@@H] (O[C@@H] 5O[C@H] (CO) [C@H] (O) [C@H] (O) [C@H] 5O) [C@H] (O) [C@H] 4NC(C) =O) [C@@H] (O) [C@H] (O[C@H] 4O[C@H] (CO) [C@@H] (O) [C@H] (O) [C@@H] 4O[C@@H] 4O[C@H] (CO) [C@@H] (O[C@@H] 5O[C@H] (CO) [C@H] (O) [C@H] (O) [C@H] 5O) [C@H] (O) [C@H] 4NC(C) =O) [C@@H] 3O) [C@H] (O) [C@H] 2NC(C) =O) [C@@H] (O) [C@H] (O) [C@@H] 1O |
|
View more via ChEBI Ontology
Outgoing
|
β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→3)- [β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→6)]- β- D- Man- (1→4)- β- D- GlcpNAc- (1→4)- [α- L- Fucp- (1→6)]- β- D- GlcpNAc
(CHEBI:70967)
has role
epitope
(CHEBI:53000)
β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→3)- [β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→6)]- β- D- Man- (1→4)- β- D- GlcpNAc- (1→4)- [α- L- Fucp- (1→6)]- β- D- GlcpNAc
(CHEBI:70967)
is a
N-glycan derivative
(CHEBI:71275)
β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→3)- [β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→6)]- β- D- Man- (1→4)- β- D- GlcpNAc- (1→4)- [α- L- Fucp- (1→6)]- β- D- GlcpNAc
(CHEBI:70967)
is a
amino decasaccharide
(CHEBI:68691)
β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→3)- [β- D- Galp- (1→4)- β- D- GlcpNAc- (1→2)- α- D- Manp- (1→6)]- β- D- Man- (1→4)- β- D- GlcpNAc- (1→4)- [α- L- Fucp- (1→6)]- β- D- GlcpNAc
(CHEBI:70967)
is a
glucosamine oligosaccharide
(CHEBI:22485)
|
|
β- D- galactopyranosyl- (1→4)- 2- acetamido- 2- deoxy- β- D- glucopyranosyl- (1→2)- α- D- mannopyranosyl- (1→6)- [β- D- galactopyranosyl- (1→4)- 2- acetamido- 2- deoxy- β- D- glucopyranosyl- (1→2)- α- D- mannopyranosyl- (1→3)]- β- D- mannopyranosyl- (1→4)- 2- acetamido- 2- deoxy- β- D- glucopyranosyl- (1→4)- [α- L- fucopyranosyl- (1→6)]- 2- acetamido- 2- deoxy- β- D- glucopyranose
|
β- D- Gal- (1→4)- β- D- GlcNAc- (1→2)- α- D- Man- (1→3)- [β- D- Gal- (1→4)- β- D- GlcNAc- (1→2)- α- D- Man- (1→6)]- β- D- Man- (1→4)- β- D- GlcNAc- (1→4)- [α- L- Fuc- (1→6)]- β- D- GlcNAc
|
ChEBI
|
β- D- Gal- (1→4)- β- D- GlcNAc- (1→2)- α- D- Man- (1→6)- [β- D- Gal- (1→4)- β- D- GlcNAc- (1→2)- α- D- Man- (1→3)]- β- D- Man- (1→4)- β- D- GlcNAc- (1→4)- [α- L- Fuc- (1→6)]- β- D- GlcNAc
|
ChEBI
|
β- D- galactopyranosyl- (1→4)- 2- acetamido- 2- deoxy- β- D- glucopyranosyl- (1→2)- α- D- mannopyranosyl- (1→6)- [β- D- galactopyranosyl- (1→4)- 2- acetamido- 2- deoxy- β- D- glucopyranosyl- (1→2)- α- D- mannopyranosyl- (1→3)]- β- D- mannopyranosyl- (1→4)- 2- acetamido- 2- deoxy- β- D- glucopyranosyl- (1→4)- [6- deoxy- α- L- galactopyranosyl- (1→6)]- 2- acetamido- 2- deoxy- β- D- glucopyranose
|
IUPAC
|
β- D- galactosyl- (1→4)- N- acetyl- β- D- glucosaminyl- (1→2)- α- D- mannosyl- (1→3)- [β- D- galactosyl- (1→4)- N- acetyl- β- D- glucosaminyl- (1→2)- α- D- mannosyl- (1→6)]- β- D- mannosyl- (1→4)- N- acetyl- β- D- glucosaminyl- (1→4)- [α- L- fucosyl- (1→6)]- N- acetyl- β- D- glucosamine
|
ChEBI
|
β- D- galactosyl- (1→4)- N- acetyl- β- D- glucosaminyl- (1→2)- α- D- mannosyl- (1→6)- [β- D- galactosyl- (1→4)- N- acetyl- β- D- glucosaminyl- (1→2)- α- D- mannosyl- (1→3)]- β- D- mannosyl- (1→4)- N- acetyl- β- D- glucosaminyl- (1→4)- [α- L- fucosyl- (1→6)]- N- acetyl- β- D- glucosamine
|
ChEBI
|
Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb
|
ChEBI
|
Galβ1- 4GlcNAcβ1- 2Manα1- 3(Galβ1- 4GlcNAcβ1- 2Manα1- 6)Manβ1- 4GlcNAcβ1- 4(Fucα1- 6)GlcNAcβ
|
ChEBI
|
WURCS=2.0/5,10,9/[a2122h- 1b_1- 5_2*NCC/3=O][a1122h- 1b_1- 5][a1122h- 1a_1- 5][a2112h- 1b_1- 5][a1221m- 1a_1- 5]/1- 1- 2- 3- 1- 4- 3- 1- 4- 5/a4- b1_a6- j1_b4- c1_c3- d1_c6- g1_d2- e1_e4- f1_g2- h1_h4- i1
|
GlyTouCan
|
19443021
|
PubMed citation
|
Europe PMC
|
29187897
|
PubMed citation
|
Europe PMC
|
31537530
|
PubMed citation
|
Europe PMC
|
|